Strand Therapeutics Doses First Patients in Phase 1 Trial of STX-003, a Programmable mRNA Therapy for Solid Tumors
Strand Therapeutics, a clinical-stage biotechnology company developing programmable messenger RNA (mRNA) medicines, has announced that the first patients have been dosed in ASCENT-1, a Phase 1 clinical trial evaluating STX-003, an investigational therapy designed to activate the immune system against cancer while limiting activity in healthy tissues. The milestone marks the company’s expansion into systemically administered programmable mRNA therapeutics and the first clinical evaluation of its proprietary SignalLock genetic circuitry, which is designed to regulate where therapeutic proteins are expressed within the body.
STX-003 is an intravenously administered, self-replicating mRNA therapy engineered to selectively express interleukin-12 (IL-12) within tumors. IL-12 is a potent immune-signaling protein with established anti-tumor activity, but its development as a systemic cancer treatment has historically been constrained by safety concerns associated with widespread immune activation. Strand’s approach combines its SignalPath delivery technology with SignalLock genetic circuitry to help direct therapeutic activity toward tumor tissue while restricting expression in healthy cells.
The initiation of ASCENT-1 represents an important step in the company’s effort to expand the applications of mRNA therapeutics beyond conventional delivery strategies. By incorporating genetic instructions that respond to the biological characteristics of individual cells, Strand aims to develop medicines that can control not only which therapeutic payload is produced but also where it becomes active.
The company believes this approach could help address a longstanding challenge in systemic genetic medicine: delivering potent therapeutic agents throughout the body without exposing healthy tissues to unacceptable levels of treatment-related toxicity.
STX-003 Combines Systemic Delivery With Programmable Gene Regulation
STX-003 has been developed to address limitations associated with delivering immune-activating therapies to tumors located throughout the body. Unlike treatments administered directly into a tumor, intravenous administration is intended to allow the investigational therapy to circulate through the bloodstream and reach tumor tissue at multiple sites.
However, systemic administration presents challenges when a therapeutic payload can also affect healthy organs and tissues. For potent immune-stimulating proteins such as IL-12, controlling the location of expression is particularly important because excessive systemic exposure can lead to significant toxicity.
Strand’s platform is designed to address this issue through two complementary technologies: SignalPath delivery technology and SignalLock genetic circuitry.
SignalPath is intended to support the delivery of mRNA to tumor tissue following intravenous administration. SignalLock provides an additional layer of control by using endogenous microRNA signatures within cells to regulate therapeutic protein expression.
MicroRNAs are small RNA molecules that help regulate gene expression by influencing the stability or translation of messenger RNA. Different cell types can have distinct microRNA expression patterns, creating opportunities for therapeutic systems to distinguish between cellular environments.
Strand’s SignalLock circuitry is designed to interpret these biological signals and control whether a therapeutic payload is expressed in a particular cell. In the case of STX-003, the objective is to enable IL-12 expression in tumor cells while restricting its production in healthy tissue.
This approach differs from relying exclusively on delivery systems to determine where a medicine acts. Even if a therapeutic formulation reaches multiple tissues, programmable genetic circuitry may provide an additional mechanism for controlling where the encoded protein is produced.
The company’s broader strategy is to develop mRNA medicines that incorporate these regulatory functions directly into their design. If the approach demonstrates an acceptable safety profile and meaningful biological activity in clinical studies, it could potentially support the development of therapies involving potent payloads that have previously been difficult to administer systemically.
Nevertheless, the ability of STX-003 to selectively express IL-12 in human tumors, reduce exposure in healthy tissues and produce meaningful clinical benefits remains to be established through clinical evaluation.
CEO Highlights the Next Stage of Programmable mRNA Medicine
Jake Becraft, Ph.D., Co-founder and Chief Executive Officer of Strand Therapeutics, described the first patient dosing milestone as an important development in the company’s efforts to advance programmable mRNA medicines.
“This milestone represents an important step toward what we believe is the next frontier for mRNA medicines as we program not just what a medicine expresses, but where it is active,” said Becraft.
He explained that STX-003 combines the company’s core technologies to address the challenge of systemically delivering mRNA beyond the liver while controlling therapeutic activity at the cellular and tissue levels.
According to Becraft, the approach is intended to overcome a limitation that has affected the development of systemic mRNA therapeutics for several years. Conventional delivery approaches may transport a therapeutic payload to particular tissues, but achieving precise control over the subsequent biological activity can be more difficult.
By integrating delivery technology with programmable gene regulation, Strand aims to make the location of therapeutic expression a central component of drug design.
Becraft added that successful clinical validation could open the door to a new category of programmable medicines and enable the use of therapeutic payloads whose development has been limited by systemic toxicity.
The current Phase 1 study will be important in determining whether the company’s design can achieve the intended balance between therapeutic activity and tolerability in patients with advanced solid tumors.
SignalLock Adds a Layer of Control to Systemic Genetic Medicines
Tasuku Kitada, Ph.D., MBA, Co-founder, President and Head of Research and Development at Strand Therapeutics, emphasized that precise control over therapeutic activity is a central challenge in systemic genetic medicine.
“The central challenge in systemic genetic medicine is not simply getting a therapeutic into the body; it is achieving precise control over where that therapeutic becomes active,” said Kitada.
He explained that SignalLock was developed to provide an additional level of regulation by enabling a medicine to interpret the biological characteristics of the cells it encounters.
The first clinical evaluation of STX-003 will allow Strand to investigate whether this regulatory approach can be applied systemically in patients. It also represents a step toward testing the broader potential of programmable mRNA medicines in clinical settings.
The underlying concept is that a therapeutic system should do more than deliver genetic instructions. It should also incorporate mechanisms that influence when and where those instructions result in the production of a therapeutic protein.
Such control could be especially relevant for medicines that stimulate immune responses, alter cellular pathways or produce proteins with potentially harmful effects if expressed in unintended tissues.
For cancer immunotherapy, selective expression could help concentrate immune-activating activity within tumors while reducing unwanted effects elsewhere in the body. However, the degree of selectivity achieved in patients, and its relationship to safety and efficacy, will need to be assessed through the clinical data generated by ASCENT-1.
STX-003 Builds on Clinical Experience With STX-001
The development of STX-003 builds on Strand Therapeutics’ clinical experience with STX-001, the company’s intratumorally administered self-replicating mRNA therapy designed to express IL-12.
STX-001 is administered directly into tumors, with the aim of generating localized production of the immune-activating protein. In patients with advanced solid tumors whose disease progressed following previous treatments, the company has reported preliminary evidence of systemic immune activation and anti-tumor activity.
According to Strand, these preliminary findings have included responses in tumors that were not directly injected. Such observations are relevant because they suggest that localized IL-12 expression may stimulate immune responses extending beyond the treated tumor.
The possibility of generating systemic anti-tumor activity through local immune activation is an important area of investigation in cancer immunotherapy. If an immune response can be initiated or strengthened at one tumor site and subsequently affect other disease sites, it could offer a way to address cancer that has spread throughout the body.
However, preliminary observations from an early clinical program do not establish the magnitude, durability or generalizability of a treatment effect. Further clinical evaluation is necessary to determine the consistency of the findings and identify which patients may benefit.
STX-003 is designed to build on these earlier experiences by moving from direct intratumoral administration to systemic intravenous delivery.
The objective is to bring the same IL-12-based therapeutic concept to tumors throughout the body while incorporating SignalLock circuitry to regulate where the protein is expressed.
This represents a meaningful development step because systemic administration may offer a different route to treating patients with multiple tumor sites, including lesions that cannot be readily accessed for direct injection.
At the same time, systemic delivery introduces additional safety and pharmacological questions. The investigational therapy must reach relevant tumor tissues, produce sufficient therapeutic activity and avoid unacceptable effects in healthy organs.
ASCENT-1 is intended to provide initial clinical information addressing these questions.
Chief Medical Officer Discusses the Objectives of ASCENT-1
Jason Luke, M.D., Chief Medical Officer at Strand Therapeutics, said the company’s experience with STX-001 has provided important clinical evidence supporting further investigation of sustained IL-12 expression.
“Our experience with STX-001 has given us important clinical evidence that sustained, local IL-12 expression can generate systemic immune and anti-tumor activity,” said Luke.
He noted that STX-003 is intended to build on those findings by enabling systemic administration while using programmable genetic circuitry to control where IL-12 is expressed.
According to Luke, ASCENT-1 will allow the company to evaluate the therapy’s safety, pharmacology and biological activity while establishing an optimized dose and informing subsequent clinical development.
The study is expected to provide information that will help determine how the investigational therapy behaves following intravenous administration, how patients tolerate different dose levels and whether early evidence of anti-tumor activity can be observed.
These findings will be important for determining the appropriate direction of the STX-003 development program. Early-stage studies are not generally designed to establish definitive efficacy, but they can help identify dose levels suitable for additional evaluation and characterize potential safety concerns.
ASCENT-1 Evaluates Safety and Preliminary Anti-Tumor Activity
ASCENT-1 is a Phase 1, multiple-ascending-dose study evaluating intravenously administered STX-003 in adults with advanced solid tumors.
The study is enrolling patients with measurable, locally advanced or metastatic solid tumors for which an anti-PD-1 or anti-PD-L1 therapy is approved and who have no remaining curative treatment options.
Anti-PD-1 and anti-PD-L1 medicines are immune checkpoint inhibitors that help restore or strengthen the immune system’s ability to recognize and attack cancer cells. These therapies have become important treatment options across several cancer types, although many patients experience disease progression despite treatment.
The ASCENT-1 eligibility criteria focus on patients whose cancers fall within settings where checkpoint inhibitor treatment is approved and for whom curative options are unavailable.
The trial is open at three clinical sites in the United States and one site in Australia, giving the study an international recruitment footprint.
Additional information about the trial is available through ClinicalTrials.gov under identifier NCT07751042.
The Phase 1 study is designed to evaluate several important parameters:
- Safety and tolerability: Assessing adverse events and determining how well participants tolerate the investigational therapy at different dose levels.
- Pharmacokinetics: Examining how STX-003 behaves in the body following intravenous administration.
- Pharmacodynamics: Investigating biological effects associated with treatment, including evidence relevant to IL-12 activity and immune-system engagement.
- Preliminary anti-tumor activity: Exploring early signs of potential treatment effects in patients with advanced solid tumors.
The multiple-ascending-dose design allows investigators to evaluate progressively higher dose levels according to the study protocol. The resulting data can help inform dose selection and determine whether additional investigation is warranted.
As the trial progresses, the company expects the findings to guide dose optimization and establish a clinical development pathway for STX-003.
Investigator Highlights Unmet Needs After Checkpoint Inhibitors
Justin Moser, M.D., an investigator from HonorHealth Research Institute participating in the study, highlighted the need for new treatment approaches for patients with advanced solid tumors that continue to progress following immune checkpoint inhibitor therapy.
“Patients with advanced solid tumors that progress after checkpoint inhibitors need new options,” said Moser.
He explained that the study will evaluate whether programmable RNA can concentrate IL-12 activity inside tumors while keeping toxicity within an acceptable range.
This balance is central to the development of STX-003. IL-12 can stimulate immune responses with potential anti-tumor effects, but systemic exposure has historically created challenges for its clinical use.
The ability to regulate the location of IL-12 production could potentially address some of these limitations. If the approach works as intended, it may allow the therapy to activate immune mechanisms in tumor tissue without producing excessive activity in healthy organs.
The study will need to establish whether the technology can achieve this balance in humans. Relevant findings will include the frequency and severity of adverse events, evidence of biological activity and any preliminary signals of tumor response.
The results will also help determine whether the combination of systemic delivery and programmable expression provides a sufficient rationale for further clinical development.
Rapid Transition From IND Clearance to Clinical Evaluation
Strand Therapeutics reported that STX-003 advanced from Investigational New Drug clearance into clinical development rapidly, with the first patient dosed approximately eight weeks after clearance.
The transition demonstrates the company’s progress in moving the program from regulatory preparation into human testing. The first dosing milestone also begins the process of generating clinical evidence for the SignalLock circuitry in a systemic treatment setting.
While the pace of development is an operational milestone, the program’s future progress will depend on the quality of the clinical data, including whether the treatment demonstrates acceptable safety and a biological profile that supports further investigation.
The company expects its initial development efforts to focus on non-small cell lung cancer (NSCLC) and cutaneous melanoma.
NSCLC is the most common broad category of lung cancer and includes several distinct disease subtypes. Cutaneous melanoma is a form of skin cancer arising from pigment-producing cells. Both diseases can progress to advanced stages, and treatment outcomes vary depending on disease characteristics, prior treatment and individual patient factors.
These indications provide potential settings in which to investigate the effects of an immune-activating therapy designed for systemic delivery. However, the selection of these initial development priorities does not establish that STX-003 will be effective in either cancer type.
Next Steps for Strand Therapeutics
The first patients dosed in ASCENT-1 mark an important milestone in Strand Therapeutics’ strategy to develop programmable mRNA medicines that combine therapeutic protein expression with cellular-level control.
STX-003 brings together self-replicating mRNA, SignalPath delivery technology and SignalLock genetic circuitry to pursue selective IL-12 expression in tumors following intravenous administration. Its development builds on the company’s earlier experience with intratumoral STX-001 while seeking to address the additional challenges associated with systemic delivery.
The immediate priority is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity during dose escalation. These results will help determine the appropriate dose and inform decisions about subsequent clinical studies.
For patients with advanced solid tumors who have exhausted available treatment options, new immunotherapy approaches remain an important area of research. Yet the potential of STX-003 will depend on whether the programmable system can deliver meaningful biological activity without unacceptable toxicity.
If clinical studies validate the approach, Strand’s platform could support further investigation of mRNA medicines designed to regulate therapeutic activity according to the biological characteristics of specific tissues.
For now, ASCENT-1 represents the first clinical test of SignalLock in a systemically administered therapy and a key step in determining whether programmable mRNA technology can expand the range of potent therapeutic approaches available for cancer treatment.
About Strand Therapeutics
Strand Therapeutics is a clinical-stage biotechnology company pioneering programmable mRNA therapeutics to realize the full potential of genetic medicines. Strand’s proprietary Signal Stack platform, which includes EverScript circular RNA, AmpliScript self-replicating RNA, SignalPath targeted delivery and logic-driven SignalLock genetic circuits, provides multiple approaches for controlling therapeutic activity across tissues and cell types to address foundational limits in targeting, durability and safety.
The company is advancing a pipeline focused on oncology and autoimmune disease. Its lead clinical program, STX-003, is a systemically delivered self-replicating mRNA therapy expressing IL-12 and leveraging Strand’s SignalLock circuitry to enable tumor-selective therapeutic activity. Strand is also advancing STX-005, an in vivo CAR-T program designed to combine targeted delivery with controlled, durable and re-dosable CAR expression.
Strand’s first clinical program, STX-001, provides preliminary clinical evidence of systemic immune activation and anti-tumor activity from locally expressed IL-12 and helped establish the foundation for STX-003. Founded by MIT synthetic biology pioneers, Strand has raised over $250 million and is headquartered in Boston, MA.